FDA Policy and Cardiovascular Medicine

Affiliations

¹ From Section of General Internal Medicine and the Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine; Department of Health Policy and Management, Yale University School of Public Health; and Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (J.S.R.); and Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (A.S.K.). joseph.ross@yale.edu.
² From Section of General Internal Medicine and the Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine; Department of Health Policy and Management, Yale University School of Public Health; and Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (J.S.R.); and Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (A.S.K.).

Review

Joseph S Ross et al. Circulation. 2015.

. 2015 Sep 22;132(12):1136-45.

doi: 10.1161/CIRCULATIONAHA.114.010295.

¹ From Section of General Internal Medicine and the Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine; Department of Health Policy and Management, Yale University School of Public Health; and Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (J.S.R.); and Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (A.S.K.). joseph.ross@yale.edu.
² From Section of General Internal Medicine and the Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine; Department of Health Policy and Management, Yale University School of Public Health; and Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (J.S.R.); and Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (A.S.K.).

No abstract available

Keywords: health policy; medical therapy; pharmaceutical safety.

References

1. U.S. Food and Drug Administration. FDA Organizational Histories. [Accessed January 7, 2015];2013 Aug; http://www.fda.gov/AboutFDA/WhatWeDo/History/FOrgsHistory/default.htm.
1. Federal Food and Drugs Act, Pub. L. No. 59-384, 34 Stat. 768. 1906
1. Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, 52 Stat. 1040. 1938
1. Drug Amendments Act, Pub. L. No. 87-781, 76 Stat. 780. 1962
1. Medical Device Amendments, Pub. L. No. 94-295, 90 Stat. 539. 1976